Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Cash from Operations (2016 - 2025)

Integra Lifesciences Holdings' Cash from Operations history spans 17 years, with the latest figure at 11816000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 76.71% year-over-year to 11816000.0; the TTM value through Dec 2025 reached 50384000.0, down 61.06%, while the annual FY2025 figure was 50384000.0, 61.06% down from the prior year.
  • Cash from Operations for Q4 2025 was 11816000.0 at Integra Lifesciences Holdings, down from 40906000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 91290000.0 in Q2 2021 and bottomed at 11257000.0 in Q1 2025.
  • The 5-year median for Cash from Operations is 42625000.0 (2022), against an average of 44830850.0.
  • The largest annual shift saw Cash from Operations skyrocketed 231.9% in 2021 before it crashed 171.45% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 69277000.0 in 2021, then increased by 23.18% to 85334000.0 in 2022, then plummeted by 31.15% to 58750000.0 in 2023, then decreased by 13.63% to 50740000.0 in 2024, then plummeted by 76.71% to 11816000.0 in 2025.
  • Per Business Quant, the three most recent readings for IART's Cash from Operations are 11816000.0 (Q4 2025), 40906000.0 (Q3 2025), and 8919000.0 (Q2 2025).